YW
Therapeutic Areas
HUTCHMED Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Fruquintinib (ELUNATE®) | Metastatic Colorectal Cancer (3L+) | Approved |
| Fruquintinib | Metastatic Colorectal Cancer (2L) | Phase 3 |
| Savolitinib (ORPATHYS®) | NSCLC with MET exon 14 skipping alterations | Approved |
| Savolitinib | Papillary Renal Cell Carcinoma | Phase 3 |
| Surufatinib (SULANDA®) | Advanced Neuroendocrine Tumors (pan-NET, epNET) | Approved |
| Surufatinib | Biliary Tract Cancer, Osteosarcoma, Thyroid Cancer | Phase 2/3 |
| HMPL-306 | IDH1/2 Double Mutant Hematological & Solid Tumors | Phase 1 |
| HMPL-760 | B-cell Malignancies | Phase 1 |
Leadership Team at HUTCHMED
ST
Simon To
Chairman of the Board
WS
Weiguo Su
Chief Executive Officer & Chief Scientific Officer
JC
Johnny Cheng
Chief Financial Officer
MS
Michael Shi
Chief Medical Officer & Head of Global Development
SD
Samantha Du
Founder and Non-Executive Director
KA
Karen Atkin
Non-Executive Director, Chair of Audit Committee
DE
Dan Eldar
Senior Vice President, Business Development
HZ
Hui Zhou
Senior Vice President, Regulatory Affairs
LZ
Li Zheng
Senior Vice President, Translational Medicine
MK
Marek Kania
Senior Vice President, Global Head of Medical Affairs